Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update

NEXT STORY
Hemispherx Reports 2018 Year-end Financial Results
PREV STORY
Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma

TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a ...

author_avatar
NASDAQ Market News

Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting

author_avatar
NASDAQ Market News

Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

author_avatar
NASDAQ Market News